Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2021

01-07-2021 | Herpes Virus | Therapy in Practice

Viral Venereal Diseases of the Skin

Authors: Theodora K. Karagounis, Miriam K. Pomeranz

Published in: American Journal of Clinical Dermatology | Issue 4/2021

Login to get access

Abstract

Viral venereal diseases remain difficult to treat. Human papilloma virus (HPV) and herpes simplex virus (HSV) are two common viral venereal diseases. HPV infections are characterized by anogenital warts and less commonly by premalignant or malignant lesions. HSV infections classically present as grouped vesicles on an erythematous base with associated burning or pain; however, immunosuppressed patients may have atypical presentations with nodular or ulcerative lesions. This review discusses the epidemiology, diagnosis, and management of anogenital HPV and HSV infections with an emphasis on treatment modalities for the practicing dermatologist. Diagnosis of these diseases typically relies on clinical assessment, although multiple diagnostic techniques can be utilized and are recommended when diagnosis is uncertain or evaluating an individual with increased risk of malignancy. Management of HPV and HSV infections involves appropriate counseling, screening, and multiple treatment techniques. Particularly for HPV infections, a practitioner may need to use a combination of techniques to achieve the desired outcome.
Literature
1.
Chen Z, DeSalle R, Schiffman M, Herrero R, Wood CE, Ruiz JC, et al. Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathog. 2018;14:e1007352.PubMedPubMedCentral
2.
Wertheim JO, Smith MD, Smith DM, Scheffler K, Kosakovsky Pond SL. Evolutionary origins of human herpes simplex viruses 1 and 2. Mol Biol Evol. 2014;31:2356–64.PubMedPubMedCentral
3.
Bowden R, Sakaoka H, Ward R, Donnelly P. Patterns of Eurasian HSV-1 molecular diversity and inferences of human migrations. Infect Genet Evol. 2006;6:63–74.PubMed
4.
5.
Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of vulvar squamous intraepithelial lesions. Obstet Gynecol. 2016;127:264–8.PubMed
6.
Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: Background and consensus recommendations from the college of American pathologists and the American society for colposcopy and cervical pathology. Int J Gynecol Pathol. 2013;32:76–115.PubMed
7.
8.
Wilkinson EJ, Cox JT, Selim MA, O’Connor DM. Evolution of terminology for human-papillomavirus-infection-related vulvar squamous intraepithelial lesions. J Low Genit Tract Dis. 2015;19:81–7.PubMed
9.
Wieland U, Jurk S, Weissenborn S, Pfister H, Krieg T, Ritzkowsky A. Erythroplasia of Queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol. 2000;115:396–401.PubMed
10.
Grassegger A, Höpfl R, Hussl H, Wicke K, Fritsch P. Buschke—Loewenstein tumour infiltrating pelvic organs. Br J Dermatol. 1994;130:221–5.PubMed
11.
Vidal CI, Armbrect EA, Andea AA, Bohlke AK, Comfere NI, Hughes SR, et al. Appropriate use criteria in dermatopathology: initial recommendations from the American Society of Dermatopathology. J Am Acad Dermatol. 2019;80:189-207.e11.PubMed
12.
Szentirmay Z, Pólus K, Tamás L, Szentkuti G, Kurcsics J, Csernák E, et al. Human papillomavirus in head and neck cancer: Molecular biology and clinicopathological correlations. Cancer Metast Rev. 2005;24:19–34.
13.
Mui U, Haley C, Tyring S. Viral oncology: molecular biology and pathogenesis. J Clin Med. 2017;6:111.PubMedCentral
14.
Stubenrauch F, Laimins LA. Human papillomavirus life cycle: Active and latent phases. Semin Cancer Biol. 1999;9:379–86.PubMed
15.
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.PubMed
16.
Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Hgødall E, Geertsen PF, Havsteen H. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol. 2014;32:1812–7.PubMed
17.
Halec G, Alemany L, Quiros B, Clavero O, Höfler D, Alejo M, et al. Biological relevance of human papillomaviruses in vulvar cancer. Mod Pathol. 2017;30:549–62.PubMed
18.
Aynaud O, Ionesco M, Barrasso R. Penile intraepithelial neoplasia. Specific clinical features correlate with histologic and virologic findings. Cancer. 1994;74:1762–7.PubMed
19.
Chan KW, Lam KY, Chan ACL, Lau P, Srivastava G. Prevalence of human papillomavirus types 16 and 18 in penile carcinoma: A study of 41 cases using PCR. J Clin Pathol. 1994;47:823–6.PubMedPubMedCentral
20.
Micali G, Nasca MR, Innocenzi D, Schwartz RA. Penile cancer. J Am Acad Dermatol. 2006;54:369–91.PubMed
21.
Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001;8:209–20.PubMedPubMedCentral
22.
Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015;74:1360–7.PubMed
23.
Wadström H, Frisell T, Sparén P, Askling J. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann Rheum Dis. 2016;75:1272–8.PubMed
24.
Matorras R, Ariceta JM, Rementeria A, Corral J, de Terán GG, Diez J, et al. Human immunodeficiency virus-induced immunosuppression: a risk factor for human papillomavirus infection. Am J Obstet Gynecol. 1991;164:42–4.PubMed
25.
Halpert RG, Fruchter RG, Sedlis A, Butt K, Boyce JC, Sillman FH. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol. 1986;68:251–8.PubMed
26.
Wadström H, Arkema EV, Sjöwall C, Askling J, Simard JF. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatol (United Kingdom). 2017;56:613–9.
27.
Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–10.PubMed
28.
Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32:7.
29.
Oriel JD. Natural history of genital warts. Sex Transm Infect. 1971;47:1–13.
30.
Arima Y, Winer RL, Feng Q, Hughes JP, Lee SK, Stern ME, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis. 2010;202:1181–4.PubMed
31.
Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191:731–8.PubMed
32.
Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24:52–61.
33.
Winer RL, Hughes JP, Feng Q, O’Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645–54.PubMed
34.
Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis. 2004;31:601–7.PubMed
35.
Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41:660–4.PubMedPubMedCentral
36.
Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582–9.PubMed
37.
Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health. 2018;108:112–9.PubMedPubMedCentral
38.
Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397–403.PubMed
39.
Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23:1107–22.PubMed
40.
Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191:105–13.PubMed
41.
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal. 2020;8:e191-203.
42.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.PubMed
43.
De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17:545–54.PubMed
44.
Gormley RH, Kovarik CL. Human papillomavirus-related genital disease in the immunocompromised host: Part I. J Am Acad Dermatol Elsevier. 2012;66:883.e1-883.e17.
45.
Dong H, Shu D, Campbell TM, Frühauf J, Soyer P, Hofmann-Wellenhof R. Dermatoscopy of genital warts. J Am Acad Dermatol. 2011;64:859–64.PubMed
46.
Leonardi CL, Zhu WY, Kinsey WH, Penneys NS. Seborrheic keratoses from the genital region may contain human papillomavirus DNA. Arch Dermatol. 1991;127:1203–6.PubMed
47.
Li J, Ackerman AB. “Seborrheic keratoses” that contain human papillomavirus are condylomata acuminata. Am J Dermatopathol. 1994;16:398–408.PubMed
48.
Reutter JC, Geisinger KR, Laudadio J. Vulvar seborrheic keratosis: Is there a relationship to human papillomavirus? J Low Genit Tract Dis. 2014;18:190–4.PubMed
49.
Cho CY, Lo YC, Hung MC, Lai CC, Chen CJ, Wu KG. Risk of cancer in patients with genital warts: a nationwide, population-based cohort study in Taiwan. PLoS ONE. 2017;12:1–15.
50.
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical cancer us preventive services task force recommendation statement. JAMA J Am Med Assoc. 2018;320:674–86.
51.
Nguyen ML, Flowers L. Cervical cancer screening in immunocompromised women. Obstet Gynecol Clin N Am. 2013;40:339–57.
52.
Moscicki AB, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2019;23:87–101.PubMed
53.
ACOG. Management of vulvar intraepithelial neoplasia. Gynaecol. Perinatol. 2016;128:1–5.
54.
Sinclair KA, Woods CR, Kirse DJ, Sinal SH. Anogenital and respiratory tract human papillomavirus infections among children: Age, gender, and potential transmission through sexual abuse. Pediatrics. 2005;116:815–25.PubMed
55.
Dominiak-Felden G, Cohet C, Atrux-Tallau S, Gilet H, Tristram A, Fiander A. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC Public Health. 2013;13:1–11.
56.
Bertolotti A, Milpied B, Fouéré S, Cabié A, Dupin N, Derancourt C. Methodologic gaps and risk of bias in randomized controlled trials of local anogenital wart treatments. J Am Acad Dermatol. 2019;81:1197–8.PubMed
57.
Barton S, Wakefield V, O’mahony C, Edwards S. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. BMJ Open. 2019;9:1–10.
58.
Jung JM, Jung CJ, Lee WJ, Won CH, Lee MW, Choi JH, et al. Topically applied treatments for external genital warts in nonimmunocompromised patients: a systematic review and network meta-analysis. Br J Dermatol. 2020;183:24–36.PubMed
59.
Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condylomata acuminata. N Engl J Med. 1986;315:1059–64.PubMed
60.
Trial AMDPC, Edin F. Recurrent condylomata acuminata treated with recombinant interferon alfa-2a. JAMA. 1991;265:2684.
61.
Stanley MA. Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27:571–7.PubMed
62.
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200.PubMed
63.
Grillo-Ardila CF, Gaitán HG, Angel-Müller E, Ruiz-Parra AI, Lethaby A. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev. 2013:CD010389.
64.
Beutner KR, Tyring SK, Trofatter KF, Douglas JM, Spruance S, Owens ML, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789–94.PubMedPubMedCentral
65.
Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 1998;134:25–30.PubMed
66.
Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas J. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38:230–9.PubMed
67.
Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, Van De Kerkhof PCM, et al. Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157:25–31.PubMedPubMedCentral
68.
Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol. 2005;141:985–93.PubMed
69.
Herrera S, Correa LA, Wolff JC, Gaviria A, Tyring SK, Sanclemente G. Effect of imiquimod in anogenital warts from HIV-positive men. J Clin Virol. 2007;39:210–4.PubMed
70.
Sanclemente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, et al. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatology Venereol. 2007;21:1054–60.
71.
Wilson L. Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. Biochemistry. 1970;9:4999–5007.PubMed
72.
Lacey CJN, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatology Venereol. 2013;27:263–70.
73.
Culp OS, Magid MA, Kaplan IW. Podophyllin treatment of condylomata Acuminata. J Urol. 1944;51:655–60.
74.
Kaplan IW. Condylomata acuminata. New Orleans Med Surg. 1942;94:388–90.
75.
Lacey CJN, Goodall RL, Ragnarson Tennvall G, Maw R, Kinghorn GR, Fisk PG, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect. 2003;79:270–5.PubMedPubMedCentral
76.
Edwards A, Atma-Ram A, Thin RN. Podophyllintoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin Med. 1988;64:263–5.PubMedPubMedCentral
77.
Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin Solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993;4:194–9.PubMed
78.
Mohanty KC. The cost effectiveness of treatment of genital warts with podophyllotoxin. Int J STD AIDS. 1994;5:253–6.PubMed
79.
Slater GE, Rumack BH, Peterson RG. Podophyllin poisoning. Systemic toxicity following cutaneous application. Obstet Gynecol. 1978;52:94–6.PubMed
80.
Moher LM, Maurer SA. Podophyllum toxicity: case report and literature review. J Fam Pract. 1979;9:237–40.PubMed
81.
Fisher AA. Severe systemic and local reactions to topical podophyllum resin. Cutis. 1981;28:233 (236, 242 passim).PubMed
82.
Rosen T. Green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications. J Drugs Dermatol. 2012;11:e55-60.PubMed
83.
Nguyen HP, Doan HQ, Brunell DJ, Rady P, Tyring SK. Apoptotic gene expression in sinecatechins-treated external genital and perianal warts. Viral Immunol. 2014;27:556–8.PubMed
84.
Rösl F, Das BC, Lengert M, Geletneky K, zur Hausen H. Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription. J Virol. 1997;71:362–70.PubMedPubMedCentral
85.
Tatti S, Stockfleth E, Beutner KR, Tawfik H, Elsasser U, Weyrauch P, et al. Polyphenon E®: A new treatment for external anogenital warts. Br J Dermatol. 2010;162:176–84.PubMed
86.
Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. 2008;111:1371–9.PubMed
87.
Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon® E in the treatment of external genital warts. J Eur Acad Dermatol Venereol. 2007;21:1404–12.PubMed
88.
Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, et al. Topical Polyphenon® E in the treatment of external genital and perianal warts: A randomized controlled trial. Br J Dermatol. 2008;158:1329–38.PubMed
89.
Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: A randomised observer blind placebo controlled study. Genitourin Med. 1991;67:297–302.PubMedPubMedCentral
90.
Damstra R, van Vloten W. Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients. J Dermatol Surg Oncol. 1991;17:273–6.PubMed
91.
Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis. 1993;20:344–5.PubMed
92.
Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: Diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35:S210–24.PubMed
93.
Duus BR, Philipsen T, Christensen JD, Lundvall F, Søndergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med. 1985;61:59–61.PubMedPubMedCentral
94.
Lindkaer JS. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet. 1985;326:1146–8.
95.
Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS. 2002;16:447–50.PubMed
96.
Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study. Br J Surg. 1989;76:1067–8.PubMed
97.
Kofoed K, Norrbom C, Forslund O, Møller C, Frøding LP, Pedersen AE, et al. Low prevalence of oral and nasal human papillomavirus in employees performing CO2-laser evaporation of genital warts or loop electrode excision procedure of cervical dysplasia. Acta Derm Venereol. 2015;95:173–6.PubMed
98.
Sawchuk WS, Weber PJ, Lowy DR, Dzubow LM. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: Detection and protection. J Am Acad Dermatol. 1989;21:41–9.PubMed
99.
Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur Arch Oto-rhino-laryngology. 1991;248:425–7.
100.
Sherrard J, Riddell L. Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts. Int J STD AIDS. 2007;18:365–8.PubMed
101.
Godley MJ, Bradbeer CS, Gellan M, Thin RNT. Cryotherapy compared with trichloroacetic acid in treating genital warts. Sex Transm Infect. 1987;63:390–2.
102.
103.
Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res. 1998;10:523–31.PubMed
104.
Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis. 2001;33:597–602.PubMed
105.
Anshelevich EE, Barbieri JS, Kovarik CL. Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: a retrospective analysis of 58 patients. J Am Acad Dermatol. 2020;84:206–7.PubMed
106.
Bienvenu B, Martinez F, Devergie A, Rybojad M, Rivet J, Bellenger P, et al. Topical use of cidofovir induced acute renal failure. Transplantation. 2002;73:661–2.PubMed
107.
Batista CS, Atallah ÁN, Saconato H, da Silva EMK. 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database Syst Rev. 2020;2010:CD006562.
108.
Recanati MA, Kramer KJ, Maggio JJ, Chao CR. Cadtharadin is superior to trichloroacetic acid for treatment of non-mucosal genital warts: a pilot randomized controlled trial. Clin Exp Obs Gynecol. 2018;45:383–6.
109.
Yang J, Guo PY, Ming ZZ, Jian YZ, Huang N, Wen DQ. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis. 2009;9:156.PubMedPubMedCentral
110.
Hasumi K. A trial of topical idoxuridine for vulvar condyloma acuminatum. BJOG An Int J Obstet Gynaecol. 1987;94:366–8.
111.
Happonen HP, Lassus A, Santalahti J, Forsstrom S, Lassus J. Topical idoxuridine for treatment of genital warts in males. A double-blind comparative study of 0.25% and 0.5% cream. Genitourin Med. 1990;66:254–6.PubMedPubMedCentral
112.
Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol. 2013;68:179–80.PubMed
113.
Lee HJ, Kim JK, Kim DH, Yoon MS. Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18). J Am Acad Dermatol. 2011;64:130–2.
114.
Creasman C, Haas PA, Fox TA, Balazs M. Malignant transformation of anorectal giant condyloma acuminatum (Buschke-Loewenstein tumor). Dis Colon Rectum. 1989;32:481–7.PubMed
115.
Chu QD, Vezeridis MP, Libbey NP, Wanebo HJ. Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the anorectal and perianal regions—analysis of 42 cases. Dis Colon Rectum. 1994;37:950–7.PubMed
116.
De Toma G, Cavallaro G, Bitonti A, Polistena A, Onesti MG, Scuderi N. Surgical management of perianal giant condyloma acuminatum (Buschke-Löwenstein tumor). Eur Surg Res. 2006;38:418–22.PubMed
117.
Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008;51:829–37.PubMed
118.
Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer. 1987;40:198–201.PubMed
119.
Kemp EA, Hakenewerth AM, Laurent SL, Gravitt PE, Stoerker J. Human papillomavirus prevalence in pregnancy. Obstet Gynecol. 1992;79:649–56.PubMed
120.
Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation. 11th ed. Philadelphia, PA: Wolters Kluwer; 2017.
121.
Andersson NW, Andersen JT. Association between fetal safety outcomes and exposure to local podophyllotoxin during pregnancy. JAMA Dermatol. 2020;156:303–11.PubMedPubMedCentral
122.
Ciavattini A, Tsiroglou D, Vichi M, Di Giuseppe J, Cecchi S, Tranquilli AL. Topical Imiquimod 5% cream therapy for external anogenital warts in pregnant women: report of four cases and review of the literature. J Matern Neonatal Med. 2012;25:873–6.
123.
Schwartz DB, Greenberg MD, Daoud Y, Reid R. Genital condylomas in pregnancy: Use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol. 1988;158:1407–16.PubMed
124.
Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101:645–52.PubMed
125.
Patsner B, Baker DA, Orr JW. Human papillomavirus genital tract infections during pregnancy. Clin Obstet Gynecol. 1990;33:258–67.PubMed
126.
127.
128.
Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26:541–53.PubMed
129.
Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)- 1 and HSV-2 in the genital region. J Infect Dis. 1998;177:1069–72.PubMed
130.
Frampton AR, Goins WF, Nakano K, Burton EA, Glorioso JC. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther. 2005;12:891–901.PubMed
131.
Roizman B, Whitley RJ. An inquiry into the molecular basis of HSV latency and reactivation. Annu Rev Microbiol. 2013;67:355–74.PubMed
132.
Doll JR, Hoebe K, Thompson RL, Sawtell NM. Resolution of herpes simplex virus reactivation in vivo results in neuronal destruction. PLoS Pathog. 2020;16:1–28.
133.
Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342:844–50.PubMed
134.
Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA J Am Med Assoc. 2011;305:1441–9.
135.
Wald A, Ericsson M, Krantz E, Selke S, Corey L. Oral shedding of herpes simplex virus type 2. Sex Transm Infect. 2004;80:272–6.PubMedPubMedCentral
136.
Docherty JJ, Trimble JJ, Roman SR, Faulkner SC, Naugle FP, Mundon FK, et al. Lack of oral HSV-2 in a college student population. J Med Virol. 1985;16:283–7.PubMed
137.
138.
Mertz GJ, Coombs RW, Ashley R, Jourden J, Remington M, Winter C, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis. 1988;157:1169–77.PubMed
139.
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333:770–5.PubMed
140.
Mertz GJ, Beneditti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116:197–202.PubMed
141.
Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med. 1992;116:433.PubMedPubMedCentral
142.
Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. Genital shedding of herpes simplex virus among men. J Infect Dis. 2002;186:S34–9.PubMed
143.
Krone MR, Wald A, Tabet SR, Paradise M, Corey L, Celum CL. Herpes simplex virus type 2 shedding in human immunodeficiency virus—negative men who have sex with men: frequency, patterns, and risk factors. Clin Infect Dis. 2000;30:261–7.PubMed
144.
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11–20.PubMed
145.
Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM, Self SG, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One. 2008;3:e2230.PubMedPubMedCentral
146.
Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73–83.PubMed
147.
Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: A meta-analysis. J Infect Dis. 2002;185:45–52.PubMed
148.
Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis. 1994;169:956–61.PubMed
149.
Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007;21:589–98.PubMed
150.
Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. J Am Med Assoc. 1998;280:61–6.
151.
Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Bañez Ocfemia CM, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187–93.PubMed
152.
McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. NCHS Data Brief. 2018:1–8.
153.
Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. J Am Med Assoc. 2006;296:964–73.
154.
Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2-United States, 1999–2010. J Infect Dis. 2014;209:325–33.PubMed
155.
Corey L, Adams H, Brown Z, Holmes K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98:958.PubMed
156.
Johnston C, Magaret A, Selke S, Remington M, Corey L, Wald A. Herpes simplex virus viremia during primary genital infection. J Infect Dis. 2008;198:31–4.PubMed
157.
Lautenschlager S, Eichmann A. The heterogeneous clinical spectrum of genital herpes. Dermatology. 2001;202:211–9.PubMed
158.
159.
Legoff J, Péré H, Bélec L. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J. 2014;11:83.PubMedPubMedCentral
160.
Ngo TD, Laeyendecker O, La H, Hogrefe W, Morrow RA, Quinn TC. Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein g in a low-risk population in Hanoi. Vietnam Clin Vaccine Immunol. 2008;15:382–4.PubMed
161.
Durdu M, Baba M, Seçkin D. The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions. J Am Acad Dermatol. 2008;59:958–64.PubMed
162.
Noyan MA, Durdu M, Eskiocak AH. TzanckNet: a convolutional neural network to identify cells in the cytology of erosive-vesiculobullous diseases. Sci Rep. 2020;10:1–7.
163.
Burrows J, Nitsche A, Bayly B, Walker E, Higgins G, Kok T. Detection and subtyping of Herpes simplex virus in clinical samples byLightCycler PCR, enzyme immunoassay and cell culture. BMC Microbiol. 2002;2:1–7.
164.
Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978;253:8721–7.PubMed
165.
Tyring SK, Douglas JM, Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol. 1998;134:185–91.PubMed
166.
Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006;42:8–13.PubMed
167.
Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl J Med. 1983;308:916–21.PubMed
168.
Fife K, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Sex Transm Dis. 1997;24:481–6.PubMed
169.
Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. JAMA J Am Med Assoc. 1984;251:2103.
170.
Fife KH, Almekinder J, Ofner S. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis. 2007;34:297–301.PubMed
171.
Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran S. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. JAMA. 1996;276:44.PubMed
172.
Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984;310:1551–6.PubMed
173.
Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114–28.PubMedPubMedCentral
174.
Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH. Herpes simplex virus resistant to acyclovir. A study in tertiary care center. Ann Intern Med. 1990;112:416–22.PubMed
175.
Chen Y, Scieux C, Garrait V, Socié G, Rocha V, Molina J, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis. 2000;31:927–35.PubMed
176.
Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother. 1992;36:1589–95.PubMedPubMedCentral
177.
Safrin S, Elbeik T, Phan L, Robinson D, Rush J, Elbaggari A, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1994;38:1246–50.PubMedPubMedCentral
178.
Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 1997;176:892–8.PubMed
179.
Castelo-Soccio L, Bernardin R, Stern J, Goldstein S, Kovarik C. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol. 2010;146:124.PubMedPubMedCentral
180.
Wanat KA, Gormley RH, Rosenbach M, Kovarik CL. Intralesional cidofovir for treating extensive genital verrucous herpes simplex virus infection. JAMA Dermatol. 2013;149:881–3.PubMed
181.
Wagstaff AJ, Bryson HM. Foscarnet—a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199–226.PubMed
182.
Vandercam B, Moreau M, Goffin E, Marot JC, Cosyns JP, Jadoul M. Cidofovir-induced end-stage renal failure. Clin Infect Dis. 1999;29:948–9.PubMed
183.
Kim JH, Schaenman JM, Ho DY, Brown JMY. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biol Blood Marrow Transplant. 2011;17:259–64.PubMed
184.
Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol. 2001;137:1015–7.PubMed
185.
Bernstein DI, Cardin RD, Smith GA, Pickard GE, Sollars PJ, Dixon DA, et al. The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model. npj Vaccines. 2020;5:1–8.
186.
Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, Debruyn G, et al. Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples. Clin Infect Dis. 2015;62:456–61.PubMedPubMedCentral
187.
Wald A, Langenberg AGM, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. J Am Med Assoc. 2001;285:3100–6.
188.
Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: A randomized controlled trial. J Infect Dis. 2013;208:1366–74.PubMedPubMedCentral
189.
Delaney S, Gardella C, Daruthayan C, Saracino M, Drolette L, Corey L, et al. A prospective cohort study of partner testing for herpes simplex virus and sexual behavior during pregnancy. J Infect Dis. 2012;206:486–94.PubMedPubMedCentral
190.
Brown ZA, Wald A, Morrow RA, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. J Am Med Assoc. 2003;289:203–9.
191.
ACOG. Management of genital herpes in pregnancy. Obstet Gynecol. 2020;135:e193-202.
192.
Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res Part A Clin Mol Teratol. 2004;70:201–7.
193.
Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery. Obstet Gynecol. 2006;108:141–7.PubMed
194.
Beymer MR, Weiss RE, Bolan RK, Rudy ET, Bourque LB, Rodriguez JP, et al. Sex on demand: Geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles county. Sex Transm Infect. 2014;90:567–72.PubMedPubMedCentral
195.
Ness RB, Smith KJ, Chang CCH, Schisterman EF, Bass DC. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sex Transm Dis. 2006;33:137–42.PubMed
196.
Lewnard JA, Berrang-Ford L. Internet-based partner selection and risk for unprotected anal intercourse in sexual encounters among men who have sex with men: a meta-analysis of observational studies. Sex Transm Infect. 2014;90:290–6.PubMed
197.
Niccolai LM, Ethier KA, Kershaw TS, Lewis JB, Meade CS, Ickovics JR. New sex partner acquisition and sexually transmitted disease risk among adolescent females. J Adolesc Health. 2004;34:216–23.PubMed
198.
Chan PA, Robinette A, Montgomery M, Almonte A, Cu-Uvin S, Lonks JR, et al. Extragenital infections caused by chlamydia trachomatis and neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol. 2016;2016:5758387.PubMedPubMedCentral
199.
Metadata
Title
Viral Venereal Diseases of the Skin
Authors
Theodora K. Karagounis
Miriam K. Pomeranz
Publication date
01-07-2021
Publisher
Springer International Publishing
Keywords
Herpes Virus
Wart
Published in
American Journal of Clinical Dermatology / Issue 4/2021
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-021-00606-7

Other articles of this Issue 4/2021

American Journal of Clinical Dermatology 4/2021 Go to the issue

Review Article

Teledermatology During COVID-19: An Updated Review

Original Research Article

Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

Review Article

Behçet Disease: An Update for Dermatologists

Original Research Article

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

Review Article

Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?

Short Communication

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study